Fundraising FoxNovartis Venture Fund — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.
BiotechBasel, CH
Thaminda(Chief Business Officer)inLaetitia Pouzol(Chief Scientific Officer)in
Co-investorsPfizer Venture InvestmentsPontifax Venture CapitalForbion
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieDeerfield Management CompanyJJDC+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.